Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
levothyroxine
levothyroxine
- Formulary
- Restricted Ermeza --> restricted to pedatrics and adults when crushing tablets is not appropriate.
- Non-formulary Tirosint-Sol --> all strengths.
- Therapeutic Interchange
- Formulary, Not Routinely Stocked: Ermeza
| Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
|---|---|---|---|---|---|---|
| Synthroid | POWDER FOR INJECTION, INJECTABLE | 200 mcg (0.2 mg), 500 mcg (0.5 mg) | ||||
| Tirosint-Sol | SOLUTION, ORAL | 13 mcg/1 mL, 25 mcg/1 mL, 50 mcg/1 mL, 75 mcg/1 mL, 88 mcg/1 mL, 100 mcg/1 mL, 112 mcg/1 mL, 125 mcg/1 mL, 137 mcg/1 mL | ||||
| Thyquidity | SOLUTION, ORAL | 100 mcg/5 mL | ||||
| Ermeza | SOLUTION, ORAL | 150 mcg/5 mL | ||||
| Tirosint-Sol | SOLUTION, ORAL | 150 mcg/1 mL, 175 mcg/1 mL, 200 mcg/1 mL | ||||
| Euthyrox | TABLET, ORAL | 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg,112 mcg, 125 mcg | ||||
| Levo-T | TABLET, ORAL | 25 mcg, 50 mcg, 75 mcg, 100 mcg, 125 mcg, 150 mcg, 200 mcg | ||||
| Levotabs | TABLET, ORAL | 25 mcg, 50 mcg, 75 mcg, 100 mcg, 125 mcg, 150 mcg, 200 mcg | ||||
| Synthroid, Leveothroid, Levoxyl, Unithroid | TABLET, ORAL | 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg | ||||
| Eltroxin | TABLET, ORAL | 50 mcg, 100 mcg, 150 mcg, 200 mcg, 300 mcg | ||||
| Synthroid, Leveothroid, Levoxyl, Unithroid | TABLET, ORAL | 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 mcg | ||||
| Euthyrox | TABLET, ORAL | 150 mcg, 175 mcg, 200 mcg, 300 mcg | ||||
| Levo-T | TABLET, ORAL | 300 mcg | ||||
| Levotabs | TABLET, ORAL | 300 mcg |
Last updated: Jul. 18, 2025
- Black Box Warning: Treatment of obesity or weight loss
Synthroid is approved for sample use in HH Endocrinology and Diabetes Clinics.
Levothyroxine Solutions:
NOTE (W&C): Per pediatric endocrinology, levothyroxine tablets should be used whenever possible. Orders for levothyroxine solution should be interchanged to levothyroxine tablets, following a call to the provider.
Ermeza - Use will be restricted to pediatric patients and adults who are not candidates for crushing the tablet formulation of levothyroxine. Ermeza is classified as formulary, not routinely stocked.
Thyquidity & Tirosint-Sol - Non-Formulary. Automatic interchange to Ermeza at a 1:1 ratio ONLY if tablets are unable to be used. (These formulations may be utilized in drug shortage situations if needed.)
Reviewed: 27 Aug 19 (Tirosint-Sol), July 2023 (Ermeza & Thyquidity)
Updated: July 2023 (Tirosint-Sol)
Levothyroxine Oral Solution Update
Updated: July 2025
4D1 Levothyroxine solution update.pdf